206 related articles for article (PubMed ID: 19054798)
1. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Bollée G; Patey N; Cazajous G; Robert C; Goujon JM; Fakhouri F; Bruneval P; Noël LH; Knebelmann B
Nephrol Dial Transplant; 2009 Feb; 24(2):682-5. PubMed ID: 19054798
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
3. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Vigneau C; Lorcy N; Dolley-Hitze T; Jouan F; Arlot-Bonnemains Y; Laguerre B; Verhoest G; Goujon JM; Belaud-Rotureau MA; Rioux-Leclercq N
Nephrol Dial Transplant; 2014 Feb; 29(2):325-32. PubMed ID: 24302609
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib-induced thrombotic microangiopathy.
Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R
Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017
[TBL] [Abstract][Full Text] [Related]
6. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.
Izzedine H; Escudier B; Lhomme C; Pautier P; Rouvier P; Gueutin V; Baumelou A; Derosa L; Bahleda R; Hollebecque A; Sahali D; Soria JC
Medicine (Baltimore); 2014 Nov; 93(24):333-339. PubMed ID: 25500702
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
Takahashi D; Nagahama K; Tsuura Y; Tanaka H; Tamura T
Clin Exp Nephrol; 2012 Apr; 16(2):310-5. PubMed ID: 21964704
[TBL] [Abstract][Full Text] [Related]
9. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
10. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
11. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
12. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
León-Mateos L; Mosquera J; Antón Aparicio L
Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
[TBL] [Abstract][Full Text] [Related]
13. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Grisk O; Koenen A; Meissner T; Donner A; Braun D; Steinbach A; Glöckl G; Zimmermann U; Evert K; Evert M; Katsari E; Löhn M; Plettenburg O; Rettig R
J Hypertens; 2014 Nov; 32(11):2199-210; discussion 2110. PubMed ID: 25275248
[TBL] [Abstract][Full Text] [Related]
14. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
Inoue D; Nishi H; Honda K; Ishii T; Abe H; Sato M; Nangaku M
Clin Nephrol; 2020 Jan; 93(1):47-50. PubMed ID: 31699213
[TBL] [Abstract][Full Text] [Related]
15. Allergic interstitial nephritis possibly related to sunitinib use.
Khurana A
Am J Geriatr Pharmacother; 2007 Dec; 5(4):341-4. PubMed ID: 18179992
[TBL] [Abstract][Full Text] [Related]
16. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
Mittal K; Koon H; Elson P; Triozzi P; Dowlati A; Chen H; Borden EC; Rini BI
Cancer Biol Ther; 2014 Aug; 15(8):975-81. PubMed ID: 24842548
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Gupta R; Maitland ML
Curr Hypertens Rep; 2011 Dec; 13(6):430-5. PubMed ID: 21931979
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Kapiteijn E; Brand A; Kroep J; Gelderblom H
Ann Oncol; 2007 Oct; 18(10):1745-7. PubMed ID: 17890216
[No Abstract] [Full Text] [Related]
19. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
[TBL] [Abstract][Full Text] [Related]
20. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
van der Veldt AA; van den Eertwegh AJ; Boven E
Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
